Skip to main content

Table 3 Daily and weekly questionnaire responses and corresponding P values of effects included in the analyses1

From: The effect of an acute aspirin challenge on intestinal permeability in healthy adults with and without prophylactic probiotic consumption: a double-blind, placebo-controlled, randomized trial

 

Baseline

Week 1

Week 2

Week 3

P Value2

Total GSRSa

    

W: 0.33

 Placebo

23.2 ± 1.28

22.5 ± 1.42

22.9 ± 1.46

22.4 ± 1.52

I: 0.56

 Probiotic

21.2 ± 1.36

21.7 ± 1.30

21.7 ± 1.35

20.9 ± 1.18

WxI: 0.74

Abdominal Painb

    

W: 0.56

 Placebo

1.50 ± 0.08

1.48 ± 0.13

1.49 ± 0.10

1.48 ± 0.11

I: 0.39

 Probiotic

1.37 ± 0.08

1.36 ± 0.10

1.49 ± 0.13

1.38 ± 0.09

WxI: 0.66

Diarrheac

    

W: 0.58

 Placebo

1.43 ± 0.11

1.40 ± 0.12

1.38 ± 0.09

1.37 ± 0.12

I: 0.53

 Probiotic

1.37 ± 0.10

1.28 ± 0.09

1.36 ± 0.09

1.25 ± 0.10

WxI: 0.59

Constipationd

    

W: 0.75

 Placebo

1.61 ± 0.11

1.50 ± 0.11

1.58 ± 0.15

1.58 ± 0.13

I: 0.97

 Probiotic

1.39 ± 0.09

1.47 ± 0.11

1.45 ± 0.11

1.34 ± 0.08

WxI: 0.48

Indigestione

    

W: 0.28

 Placebo

1.84 ± 0.16

1.79 ± 0.16

1.79 ± 0.16

1.73 ± 0.16

I: 0.43

 Probiotic

1.64 ± 0.16

1.78 ± 0.16

1.63 ± 0.15

1.67 ± 0.15

WxI: 0.39

Refluxf

    

W: 0.52

 Placebo

1.13 ± 0.05

1.08 ± 0.04

1.22 ± 0.08

1.12 ± 0.05

I: 0.73

 Probiotic

1.15 ± 0.05

1.14 ± 0.05

1.12 ± 0.04

1.16 ± 0.07

WxI: 0.28

DQLQg

    

W: 0.06

 Placebo

6.9 ± 2.0

7.8 ± 2.5

7.7 ± 1.9

5.9 ± 2.1

I: 0.01

 Probiotic

6.3 ± 2.2

4.6 ± 1.8

5.4 ± 2.3

4.1 ± 1.6

WxI: 0.62

BMh

    

W: 0.87

 Placebo

1.2 ± 0.1

1.2 ± 0.1

1.2 ± 0.1

1.1 ± 0.1

I: 0.94

 Probiotic

1.2 ± 0.1

1.2 ± 0.1

1.2 ± 0.1

1.2 ± 0.1

WxI: 0.37

BSFSi

    

W: 0.94

 Placebo

3.6 ± 0.2

3.7 ± 0.2

3.6 ± 0.2

3.6 ± 0.2

I: 0.34

 Probiotic

3.5 ± 0.1

3.4 ± 0.1

3.5 ± 0.2

3.5 ± 0.2

WxI: 0.67

Stressj

    

W: 0.29

 Placebo

3.3 ± 0.3

3.6 ± 0.3

3.6 ± 0.3

3.8 ± 0.4

I: 0.88

 Probiotic

3.3 ± 0.3

3.5 ± 0.3

3.6 ± 0.4

3.8 ± 0.4

WxI: 0.73

  1. 1Data represent gastrointestinal symptoms, digestion-associated quality of life, bowel movement frequency, stool form, and stress by week for each intervention. There were 3 weeks in each intervention. Baseline represents the mean score during the 2 weeks leading up to each intervention. Data were analyzed in a general linear mixed model including a random effect of participant to account for repeated measures. Baseline values were included in the model to control for potential differences in individuals at baseline. Sex was included in the model, but no interactions between sex and intervention were observed. Regardless of significance, all main effects remained in the model
  2. 2W, week; I, intervention; WxI, week by intervention
  3. aThe GSRS is a 15-item questionnaire that assesses gastrointestinal symptoms on a scale from 1 (no discomfort at all) to 7 (very severe discomfort) for five syndromes which include abdominal pain, diarrhea, constipation, indigestion, and reflux. The total represents the sum of all 15 symptoms
  4. bAbdominal pain score represents the mean score from abdominal pain, hunger pains, and nausea
  5. cDiarrhea syndrome score represents the mean score from diarrhea, loose stools, and urgent need for defecation
  6. dConstipation syndrome score represents the mean score from constipation, hard stools, and feeling of incomplete evacuation
  7. eIndigestion syndrome score represents the mean score from rumbling, bloating, burping, and gas
  8. fReflux syndrome score represents the mean score from heartburn and acid regurgitation
  9. gThe Digestion-Associated Quality of Life Questionnaire is comprised of nine questions that assess digestive events and experiences and is scored from never (zero- 0% of the time) to always (1- 100% of the time)
  10. hBM represents the mean number of bowel movements each week
  11. iBSFS is the mean daily Bristol Stool Form Scale is a measure of stool consistency (1- hard stool, 7- watery stool)
  12. jMean daily stress (0- no stress, 10- extremely stressed)
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us